Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 8;5(2):119-76.
doi: 10.3390/diagnostics5020119.

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review

Affiliations
Review

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review

Emma Elizabeth Ilett et al. Diagnostics (Basel). .

Abstract

To date, empirical literature has generally been considered lacking in relation to neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine neoplasms. NECs are often found in the lungs or the gastroenteropancreatic (GEP) system and can be of small or large cell type. Concentrating on GEP-NECs, we can conclude that survival times are poor, with a median of only 4-16 months depending on disease stage and primary site. Further, this aggressive disease appears to be on the rise, with incidence numbers increasing while survival times are stagnant. Treatment strategies concerning surgery are often undecided and second-line chemotherapy is not yet established. After an analysis of over 2600 articles, we can conclude that there is indeed more empirical literature concerning GEP-NECs available than previously assumed. This unique review is based on 333 selected articles and contains detailed information concerning all aspects of GEP-NECs. Namely, the classification, histology, genetic abnormalities, epidemiology, origin, biochemistry, imaging, treatment and survival of GEP-NECs are described. Also, organ-specific summaries with more detail in relation to disease presentation, diagnosis, treatment and survival are presented. Finally, key points are discussed with directions for future research priorities.

Keywords: Ki-67 index; colo-rectal; large cell carcinomas; neuroendocrine carcinomas; neuroendocrine neoplasms; neuroendocrine tumours; oesophagus; pancreas; small cell carcinomas; stomach.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection process of relevant articles.

References

    1. Lepage C., Rachet B., Coleman M.P. Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study. Gastroenterology. 2007;132:899–904. doi: 10.1053/j.gastro.2007.01.006. - DOI - PubMed
    1. Cho M.Y., Kim J.M., Sohn J.H., Kim M.J., Kim K.M., Kim W.H., Kim H., Kook M.C., Park D.Y., Lee J.H., et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000–2009: Multicenter Study. Cancer Res. Treat. 2012;44:157–165. doi: 10.4143/crt.2012.44.3.157. - DOI - PMC - PubMed
    1. Korse C.M., Taal B.G., van Velthuysen M.L., Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry. Eur. J. Cancer. 2013;49:1975–1983. doi: 10.1016/j.ejca.2012.12.022. - DOI - PubMed
    1. Sorbye H., Welin S., Langer S.W., Vestermark L.W., Holt N., Osterlund P., Dueland S., Hofsli E., Guren M.G., Ohrling K., et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann. Oncol. 2013;24:152–160. doi: 10.1093/annonc/mds276. - DOI - PubMed
    1. Kang H., O’Connell J., Leonardi M., Maggard M., McGory M., Ko C. Rare tumors of the colon and rectum: A national review. Int. J. Colorectal Dis. 2007;22:183–189. doi: 10.1007/s00384-006-0145-2. - DOI - PubMed

LinkOut - more resources